Zoetis Inc.

Zoetis Inc.

ZTS

$83.18

Updated: 03/11/2026, 06:37:44

Market Cap
$34.37B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US

No historical data available

Company Profile

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

USD
NYSE
CEO: Kristin C. Peck
Employees: 14,500
https://www.zoetis.com
Asset Summaries
Latest generated summaries for ZTS

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ZTS-10-k-fy2025.html3.2 MBtext/htmlENFiled 12/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 36 KPI observations

Revenue

N/A

FY — · Reported

Net income

$2.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$2.3B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$3.2B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
companion_animal_pct
Source evidence
“Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025... Livestock products represented approximately 29% of our revenue”
70N/AN/ANot disclosed by product and area
livestock_pct
Source evidence
“Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025... Livestock products represented approximately 29% of our revenue”
29N/AN/ANot disclosed by product and area
css_and_human_health_pct
Source evidence
“Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025... Livestock products represented approximately 29% of our revenue”
1N/AN/ANot disclosed by product and area

Other offerings mentioned without separate sales

Key dermatology and pain franchise products
Simparica parasiticide franchise and other key products

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global leader in animal health; ~75-year legacy; formerly a Pfizer business unit; incorporated in Delaware in July 2012

99%
Source evidence
“Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health.”

Two operating segments

U.S. and International segments; CSS contract manufacturing and human health ~1% of revenue

98%
Source evidence
“we organize and operate our business in two segments: •United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025; and •International with revenue of $4,254 million, or 45% of total revenue”

Regional market differences shaping segmentation

Segment structure reflects regional differences in customer needs, disease dynamics and regulation

90%
Source evidence
“The animal health medicines, vaccines and diagnostics market is characterized by meaningful differences in customer needs across different regions.”

Primary customers

Veterinarians and livestock producers are primary customers; trend toward concentration of veterinarians in large clinics and hospitals

95%
Source evidence
“Veterinarians and livestock producers are our primary customers. In recent years, there has been a trend towards the concentration of veterinarians in large clinics and hospitals.”

Key dermatology and pain franchise products

Dermatology/pain mAb portfolio including first-in-class Librela, Lenivia, Portela

97%
Source evidence
“Librela® (bedinvetmab), the first and only injectable mAb therapy for monthly alleviation of OA pain in dogs, was approved in the EU in 2020”

Simparica parasiticide franchise and other key products

Parasiticide, equine, swine and poultry vaccine platforms; Dectomax-CA1 conditionally approved 2025

96%
Source evidence
“Dectomax®-CA1 Injectable, the first parasite control product for the prevention and treatment of New World screwworm myiasis in cattle, received conditional approval in the U.S. from the FDA in 2025”

Companion animal vs livestock share of 2025 revenue

Companion animal ~70%, livestock ~29%, CSS/human health ~1% of 2025 revenue

98%
Source evidence
“Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025... Livestock products represented approximately 29% of our revenue”

Revenue and profit summary 2023-2025

Revenue: $9,467M (2025), $9,256M (2024), $8,544M (2023); Net income: $2,673M (2025); Adjusted net income: $2,847M (2025)

98%
Source evidence
“Revenue$9,467 $9,256 $8,544 2 8 Net income attributable to Zoetis2,673 2,486 2,344 8 6 Adjusted net income(a) 2,847 2,693 2,457 6 10”

2025 segment revenue by species

US $5,097M (83% CA/17% LC); International $4,254M (56% CA/44% LC); full country table disclosed

98%
Source evidence
“(MILLIONS OF DOLLARS)RevenueCompanion AnimalLivestock United States$5,09783%17% Total International$4,25456%44% Australia$32953%47% Brazil$39338%62%”

Operations and dependencies

Sole/exclusive source suppliers

Certain third-party suppliers may be sole or exclusive source of certain products, materials and services necessary for production

100%
Source evidence
“Certain third-party suppliers may be the sole or exclusive source of certain products, materials and services necessary for production of our products.”

Sole-sourced manufacturing

Many products are sole-sourced from certain manufacturing sites; disruptions could cause shortages, recalls and regulatory action

90%
Source evidence
“Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites.”

Positioning and strategy

Manufacturing network investment

Investing in improvements to existing manufacturing facilities and new manufacturing plants as part of supply network strategy; projects subject to delay and cost overrun risk

95%
Source evidence
“As part of our supply network strategy, we have invested and will continue to invest in improvements to our existing manufacturing facilities and in new manufacturing plants.”

Livestock demand drivers

Livestock demand driven by population growth, protein demand, resource constraints, urbanization, food safety

95%
Source evidence
“human population growth and increasing standards of living, particularly in many emerging markets;”

Companion animal demand drivers

Growth driven by pet owner spending commitment, rising disposable income in emerging markets, longer-living pets, increasing medicalization

95%
Source evidence
“increasing pet owners’ commitment to the health and well-being of their pets;”

Companion animal demand drivers

Pet care spending growth, disposable income and longer-lived pets drive companion animal demand

95%
Source evidence
“Growth in the companion animal medicines, vaccines and diagnostics sectors is driven by increases in spending on pet care, economic development and related increases in disposable income.”

Livestock demand drivers

Population growth, rising living standards and food security drive livestock protein demand

95%
Source evidence
“Human population growth and increased standards of living continue to drive demand for increased production of quality animal protein.”

Medicated feed additive divestiture

Completed divestiture of medicated feed additive portfolio on October 31, 2024

97%
Source evidence
“On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets”

Largest animal health company by revenue

Largest animal health business by revenue; competes with pharma animal health units, standalone players, generics and start-ups

95%
Source evidence
“Although our business is the largest based on revenue in the animal health industry (which includes medicines, vaccines and diagnostics), we face competition in the regions in which we operate.”

Lifecycle innovation strategy

R&D-driven lifecycle innovation; substantial share of products/revenue historically from lifecycle enhancements

94%
Source evidence
“Historically, a substantial portion of our products and revenue has been the result of product lifecycle innovation where we actively work to broaden the value of existing products”

Risks, financing, and outlook

Substantial indebtedness

~$9.2B total unsecured debt; $1.25B revolving credit facility and $1.0B commercial paper program, both undrawn

97%
Source evidence
“As of December 31, 2025, we had approximately $9.2 billion of total unsecured indebtedness outstanding related to our senior notes and convertible senior notes.”

Sanctions and humanitarian sales to Russia and Iran

Sells limited humanitarian animal health products to Russia and Iran; sanctions violations risk civil and criminal penalties

95%
Source evidence
“we sell limited humanitarian animal health products, including medicines and vaccines, to Russia and Iran”

Fiscal year alignment in 2026

2026 elimination of one-month international reporting lag; ERP transition underway

95%
Source evidence
“we expect to eliminate the one-month reporting lag in 2026 for our International Subsidiaries, effective beginning with the Company's first quarterly report in 2026”

Q4 2025 International pull-forward

International Q4 2025 sales boosted ~2.5%–3.5% by fiscal-year-alignment operational changes; non-recurring

93%
Source evidence
“led to an approximate 2.5% to 3.5% increase in sales in the International segment in the reported fourth quarter of 2025, a trend that we do not expect to recur”

Regulatory oversight of products and facilities

Manufacturing facilities subject to periodic FDA, USDA and foreign equivalent inspections; non-compliance risks include shutdowns, withdrawals, seizures

95%
Source evidence
“our manufacturing facilities are subject to periodic inspections by regulatory agencies, such as the FDA, the USDA and foreign equivalents”

EU sustainability reporting requirements

EU adopted ESRS and CSRD requiring disclosure in countries where company has interests

85%
Source evidence
“The EU adopted the European Sustainability Reporting Standards (ESRS) and the Corporate Sustainability Reporting Directive (CSRD) that will require discl”

Generic competition impact

Generic versions of Rimadyl chewable and Draxxin launched; US sales declined 39% and 66% respectively since generic competition began

100%
Source evidence
“several companies have launched generic versions of our Rimadyl chewable and Draxxin products. In the years since the start of generic and other competition, sales of our Rimadyl chewable and Draxxin products have declined in the U.S., the largest market for these products, by 39% and 66%, respectively.”

Generic competition for Draxxin

Draxxin faces generic competition in key markets; U.S. sales down 66% since 2021

97%
Source evidence
“Since 2021, the first year of generic competition, sales of Draxxin declined by 66% in the U.S., its largest market.”

Macroeconomic and geopolitical conditions

Macro/political disruptions including Russia-Ukraine war, China weakness, pandemics and inflation could adversely affect results; pet owners may defer vet visits

95%
Source evidence
“Russia's invasion of Ukraine, ongoing conflicts and rising tensions in various parts of the world, economic weakness in China, future pandemics, as well as inflation, are examples of global economic conditions that could have an adverse effect”

Animal testing regulatory risk

R&D relies on evaluations in animals; licenses/permits for animal testing could be revoked or halted; organizations seek bans or additional regulations

90%
Source evidence
“Our licenses or permits for animal testing could be revoked or put on hold due to animal welfare events that may occur.”

R&D pipeline and licensing risk

R&D, acquisition and licensing efforts may fail to generate new products; relies on collaborations/licensing for access to molecules and technology

90%
Source evidence
“We have and expect to continue to enter into collaboration or licensing arrangements with third parties to provide us with access to molecules, compounds and other technology for purposes of our business.”

Government shutdown and agency staffing risk

Prolonged government shutdown, federal workforce reductions or hiring freezes could delay regulatory submissions and approvals

90%
Source evidence
“If a prolonged government shutdown or other disruption of normal business operations occurs, it could significantly impact the ability of the USDA, FDA, EPA and other agencies to timely review and process our regulatory submissions”

Distributor/customer consolidation pricing risk

Consolidation of customers and distributors could negatively affect product pricing

90%
Source evidence
“Consolidation of our customers and distributors could negatively affect the pricing of our products.”

Material exposure graph

United States
Revenue Exposure

U.S. segment is the largest revenue source at $5,097M, 54% of total 2025 revenue, 83% companion animal.

Relevance 95·Dependency 85·Confidence 98
Source evidence
“United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025”
Companion animal customers (pet owners, veterinarians)
Revenue Exposure

Companion animal products are ~70% of revenue; growth driven by pet care spending and disposable income.

Relevance 95·Dependency 80·Confidence 98
Source evidence
“Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025.”
Top five product lines
Revenue Exposure

Concentration of revenue in five top-selling products exposes results to product-specific safety, patent or competitive issues.

Relevance 95·Dependency 80·Confidence 100
Source evidence
“our five top-selling products and product lines, Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela and our ceftiofur line, contributed approximately 42% of our revenue in 2025”
Veterinarians and livestock producers
Customer Exposure

Primary customer demand depends on vet visits, pet ownership and livestock producer economics; consolidation pressures pricing.

Relevance 90·Dependency 75·Confidence 95
Source evidence
“Veterinarians and livestock producers are our primary customers.”
Sole/exclusive third-party suppliers
Supplier Dependency

Sole or exclusive source suppliers create supply disruption risk if operations cease or are interrupted.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“Certain third-party suppliers may be the sole or exclusive source of certain products, materials and services necessary for production of our products.”
FDA/USDA animal health regulation
Regulatory Exposure

Product approvals, facility inspections and enforcement actions directly gate sales and production.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“our manufacturing facilities are subject to periodic inspections by regulatory agencies, such as the FDA, the USDA and foreign equivalents”
Generic Rimadyl/Draxxin competitors
Competitive Exposure

At-risk generic launches eroded US sales of Rimadyl chewable (39%) and Draxxin (66%); generic competition is a structural pricing/sales risk.

Relevance 85·Dependency 60·Confidence 100
Source evidence
“Generic competitors are becoming more aggressive in terms of launching at risk before patent rights expire”
Livestock producers and veterinarians
Revenue Exposure

Livestock products ~29% of revenue; demand tied to animal protein production and food security.

Relevance 80·Dependency 55·Confidence 98
Source evidence
“Livestock products represented approximately 29% of our revenue for the year ended December 31, 2025.”
Tariffs and trade policy
Cost Driver

Evolving trade policies including tariffs raise labor/material costs and may not be fully passed to customers.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“evolving trade policies (including the imposition of tariffs)”
Pet owner economic conditions
Demand Driver

Economic weakness may cause pet owners to defer vet visits, forgo treatment, or switch to lower-priced alternatives, and cause shortages of veterinary healthcare workers.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“economic concerns and geopolitical instability may cause shortages in veterinary healthcare workers or some pet owners to forgo or defer visits to veterinary practices”
Consumer spending on pet healthcare
Demand Driver

Pet owners prioritize pet healthcare spending over other lifestyle categories, supporting stable demand and enabling pricing through inflation.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“pet owners indicated a preference for reducing spending on other aspects of their lifestyle, including entertainment, clothing and household goods, before reducing spending on pet healthcare.”
Brazil
Revenue Exposure

Brazil is the largest disclosed international market at $393M revenue, 62% livestock.

Relevance 65·Dependency 45·Confidence 97
Source evidence
“Brazil$39338%62%”
Russia-Ukraine war and sanctions
Geopolitical Exposure

War, sanctions regimes and China weakness are cited macro risks; limited humanitarian sales to Russia and Iran carry sanctions compliance risk.

Relevance 65·Dependency 40·Confidence 90
Source evidence
“Russia's invasion of Ukraine, ongoing conflicts and rising tensions in various parts of the world, economic weakness in China, future pandemics, as well as inflation, are examples of global economic conditions that could have an adverse effect”
Global animal protein demand
Demand Driver

Growing global population and protein demand drive livestock health product demand.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“Livestock health and production are essential to meeting the growing demand for animal protein of a global population.”
Australia
Revenue Exposure

Australia revenue $329M, split 53% companion animal / 47% livestock.

Relevance 60·Dependency 40·Confidence 97
Source evidence
“Australia$32953%47%”
Draxxin
Competitive Exposure

Draxxin competes with generic products in key markets since 2021, with U.S. sales down 66% since generic entry.

Relevance 60·Dependency 30·Confidence 95
Source evidence
“Since 2021, the first year of generic competition, sales of Draxxin declined by 66% in the U.S., its largest market.”
United Kingdom
Revenue Exposure

UK revenue $325M, 79% companion animal.

Relevance 58·Dependency 38·Confidence 97
Source evidence
“United Kingdom$32579%21%”
China
Revenue Exposure

China capital controls could impede repatriation or conversion of cash held there, materially affecting operating results.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“place, including China, and, if we were to need to repatriate or convert such cash, these controls and restrictions may have a material adverse effect on our operating results”
China
Revenue Exposure

China revenue $227M, 72% companion animal.

Relevance 55·Dependency 30·Confidence 97
Source evidence
“China$22772%28%”
Government restrictions on antibacterial use in food-producing animals
Regulatory Exposure

Restrictions and bans on antibacterial use in food-producing animals may negatively impact ~$713M antibacterial revenue but could increase sales of antibacterial alternatives.

Relevance 50·Dependency 35·Confidence 85
Source evidence
“this issue has led to government restrictions and bans on the use of specific antibacterials in some food-producing animals, regardless of the route of administration”
OECD Pillar Two global minimum tax
Tax Exposure

OECD Pillar One and Pillar Two represent significant changes to international tax regime with risk of adverse impact to effective tax rate.

Relevance 50·Dependency 30·Confidence 90
Source evidence
“there is risk of an adverse impact to our effective tax rate as legislation becomes effective in countries in which we do business.”
Internet-based retailers and big-box retail stores
Customer Exposure

Shift of companion animal purchases from veterinarians to online and retail channels may increase sales but compress margins due to retailer purchasing power.

Relevance 50·Dependency 25·Confidence 85
Source evidence
“over time, we may be unable to sustain our current margins due to the increased purchasing power of such retailers”
Full company information
Latest profile, trading, valuation, and identifier data stored for ZTS.
Share price
$83.18
Market cap
$34.37B
Exchange
NYSE
Currency
USD
CEO
Kristin C. Peck
Employees
14,500
IPO date
01/02/2013
Beta
0.74
Last dividend
$0.00
Day range
$79.89 – $83.22
52-week range
$68.77 – $144.83
1-day performance
4.34%
1-year performance
20.95%
Current drawdown (1Y)
-42.57%
CIK
0001555280
CUSIP
98978V103
ISIN
US98978V1035
Created
07/12/2025, 15:14:54
Last update
03/11/2026, 06:37:44

Track Zoetis Inc. with an AI analyst

See which prediction-market events move ZTS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ZTS from your Railway `news_articles` table.

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

PRNewsWire • STOCK • 15/06/2026, 05:42:00

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

PRNewsWire • STOCK • 15/06/2026, 04:36:00

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Newsfile Corp • STOCK • 14/06/2026, 14:00:00

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

GlobeNewsWire • STOCK • 13/06/2026, 23:28:00

Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

Zacks Investment Research • STOCK • 12/06/2026, 21:16:12

Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire • STOCK • 12/06/2026, 17:47:00

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewsWire • STOCK • 12/06/2026, 12:24:00

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

Newsfile Corp • STOCK • 11/06/2026, 17:36:00

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

PRNewsWire • STOCK • 11/06/2026, 05:27:00

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

PRNewsWire • STOCK • 11/06/2026, 04:17:00

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

PRNewsWire • STOCK • 10/06/2026, 21:45:00

ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - RGRD Law

GlobeNewsWire • STOCK • 10/06/2026, 16:05:00